Series
Most Recent Segment
What This Means
Featuring: Sonnet BioTherapeutics
April 16, 2025
Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data related to SON-1010
What This Means
What This Means provides investors with context to press releases directly from company management teams. It also provides the opportunity for companies to communicate directly to investors and elaborate on recent key news and highlight value driving milestones.
CEO Connect
CEO Connect allows investors to hear directly from company CEOs, who will provide a brief presentation followed by an interactive Q&A session. Investors and interested parties have the opportunity to submit questions live during the event.
KOL Connect
KOL Connect features a moderated, in-depth discussion with members of the management team from participating companies along with Key Opinion Leaders.
What This Means
Featuring: Xenetic Biosciences
April 9, 2025
Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
What This Means
Featuring: Sonnet BioTherapeutics
March 26, 2025
Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas
What This Means
Featuring: Sonnet BioTherapeutics
March 19, 2025
Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid
Substitutions of its IL-18 Binding Protein Resistant Variant Protein.
CEO Connect
March 18, 2024
Marc Hertz, President and CEO of GRI Bio provided an overview of GRI’s lead program, GRI-0621, for Idiopathic Pulmonary Fibrosis (IPF), a rare chronic, progressive fibrosing interstitial lung disease with limited treatment options. Dr. Hertz highlighted near-term value driving milestones, such as interim data coming at the beginning of next quarter and topline data in the following quarter.
What This Means
Featuring: American Resources
March 7, 2025
Mark Jensen, CEO of American Resources Corporation and ReElement Technologies Corporation, discussed the Company’s production of rare earth elements and how American Resources is working to cost-effectively develop in-demand minerals for defense.
What This Means
Featuring: PalisadeBio
March 4, 2025
Dr. Joerg Heyer, Head of Translational Science and Medicine of Palisade Bio highlights preclinical data for lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC)
What This Means
Featuring: Sonnet BioTherapeutics
February 19, 2025
Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates
What This Means
Featuring: AIM ImmunoTech
February 11, 2025
Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM’s Ampligen® (rintatolimod) and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of late-stage pancreatic cancer (“DURIPANC”)
What This Means
Featuring: Outlook Therapeutics
February 4, 2025
Dr. Jennifer Kissner, SVP Clinical Development, Discusses the 12-week Safety and Efficacy Results for NORSE EIGHT Clinical Trial
What This Means
Featuring: Sonnet BioTherapeutics
January 28, 2025
Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology
What This Means
Featuring: Moleculin
January 27, 2025
Walter Klemp, CEO of Moleculin, Provides an Update on the Company’s Phase 3 Pivotal Trial of Annamycin for the Treatment of AML Patients who are Refractory to or Relapsed After Induction Therapy (R/R AML) (the “MIRACLE” trial)
What This Means
Featuring: Sonnet BioTherapeutics
January 21, 2025
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas
What This Means
Featuring: Outlook Therapeutics
January 8, 2025
Jedd Comisky, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD
What This Means
Featuring Xenetic Biosciences
December 17, 2024
Reid Bissonnette, Ph.D, Executive Consultant for Translational Research and Development at Xenetic, Discusses Extension of its Research Agreement with the University of Virgina
What This Means
Featuring Sonnet BioTherapeutics
December 9, 2024
Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial
KOL Connect
Featuring AIM ImmunoTech
December 6, 2024
Dr. Charles Lapp, ME/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center, Discussing Results from AIM’s Phase 2 Study Evaluating the Efficacy and Safety of Ampligen® as a Potential Therapeutic for People with the Post-COVID Condition of Fatigue
What This Means
Featuring Sonnet BioTherapeutics
December 4, 2024
Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action
What This Means
Featuring Xenetic Biosciences
November 22, 2024
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
What This Means
Featuring Moleculin
November 14, 2024
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025
What This Means
Featuring Sonnet BioTherapeutics
November 12, 2024
Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, Discuss the Company’s Rrecent Issuance of a U.S. Patent Covering a Variant of IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates, SON-1400 and SON-1411
KOL Connect
Featuring CNS Pharmaceuticals
November 4, 2024
Professor Michael Weller, a Leading Neuro-oncologist who Currently serves as the Chairman of the Department of Neurology at the University Hospital in Zurich, Switzerland and as the National Coordinating Investigator for CNS Pharmaceuticals’ Potentially Pivotal Study of Berubicin, Discusses the Unmet Need in Glioblastoma Multiforme (GBM), the Current Treatment Landscape and the Potential for Berubicin to Provide a Solution for this Devasting Disease
Join Us
Sign up for email alerts to stay up-to-date on the latest Virtual Investor events
By submitting this form, you are consenting to receive marketing emails from: Virtual Investor. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact